Vistagen Therapeutics Inc (VTGN)

Mar 12, 2025

Vistagen Therapeutics Inc (VTGN) Q3 FY2025 Earnings: EPS of -$0. - GuruFocus.com

Mar 12, 2025

Mar 11, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat

Mar 11, 2025

Mar 08, 2025

VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China - ACCESS Newswire

Mar 08, 2025

Mar 04, 2025

Can Vistagen's Innovative Pherine Technology Disrupt the Neuroscience Market? CEO Presents at Major Forum - StockTitan

Mar 04, 2025

Mar 02, 2025

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript - MSN

Mar 02, 2025

Feb 27, 2025

VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 - ACCESS Newswire

Feb 27, 2025

Feb 27, 2025

VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results - accessnewswire.com

Feb 27, 2025

Feb 27, 2025

VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019 - ACCESS Newswire

Feb 27, 2025

Feb 25, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat

Feb 25, 2025

Feb 20, 2025

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference - StockTitan

Feb 20, 2025

Feb 19, 2025

VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101 - ACCESS Newswire

Feb 19, 2025

Feb 18, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Announces Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat

Feb 18, 2025

Feb 15, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Stock Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat

Feb 15, 2025

Feb 15, 2025

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates - MSN

Feb 15, 2025

Feb 15, 2025

Vistagen Therapeutics Third Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Feb 15, 2025

Feb 14, 2025

VistaGen’s Earnings Call: Progress and Challenges - TipRanks

Feb 14, 2025

Feb 14, 2025

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication (NASDAQ:VTGN) - Seeking Alpha

Feb 14, 2025

Feb 14, 2025

Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo Finance

Feb 14, 2025

Feb 14, 2025

Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlight - GuruFocus.com

Feb 14, 2025

Feb 14, 2025

VistaGen Reports Q3 2025 Financial Results and Updates - TipRanks

Feb 14, 2025

Feb 13, 2025

Vistagen Reports Q3 Earnings and Pipeline Progress - TipRanks

Feb 13, 2025

Feb 13, 2025

Vistagen advances Phase 3 SAD trials with 2025 data readout target - MSN

Feb 13, 2025

Feb 13, 2025

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update - sharewise

Feb 13, 2025

Feb 13, 2025

Earnings call transcript: VistaGen Therapeutics reports Q3 FY2025 net loss - Investing.com

Feb 13, 2025

Feb 13, 2025

Vistagen Therapeutics, Inc. SEC 10-Q Report - TradingView

Feb 13, 2025

Feb 13, 2025

VistaGen Therapeutics Inc Q3 Loss Increases, But Beats Estimates - Nasdaq

Feb 13, 2025

Feb 13, 2025

Vistagen Earnings Reveal $88.6M War Chest, Phase 2A Success Fuels Pipeline Momentum - StockTitan

Feb 13, 2025

Feb 12, 2025

Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth - Yahoo Finance

Feb 12, 2025

Feb 12, 2025

Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2025 Result - Yahoo Finance

Feb 12, 2025

Feb 07, 2025

Vistagen Therapeutics (VTGN) Projected to Post Earnings on Tuesday - MarketBeat

Feb 07, 2025

Feb 06, 2025

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025 - Marketscreener.com

Feb 06, 2025

Feb 06, 2025

USPTO grants patent to Vistagen’s neuropathic pain treatment - Yahoo Finance

Feb 06, 2025

Feb 06, 2025

Q3 Earnings Preview: Vistagen to Reveal Latest Progress on Breakthrough Pherine Treatments - StockTitan

Feb 06, 2025

Feb 05, 2025

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain - sharewise

Feb 05, 2025

Feb 05, 2025

Generalized Anxiety Disorder Pipeline 2024: Mechanism - openPR

Feb 05, 2025

Feb 05, 2025

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain -February 05, 2025 at 08:38 am EST - Marketscreener.com

Feb 05, 2025

Feb 05, 2025

Vistagen secures patent for non-opioid pain treatment By Investing.com - Investing.com UK

Feb 05, 2025

Feb 05, 2025

Breakthrough Pain Treatment Patent: Vistagen's Non-Opioid AV-101 Shows Promise Against Gabapentin - StockTitan

Feb 05, 2025

Feb 04, 2025

Short Interest in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Expands By 46.2% - MarketBeat

Feb 04, 2025

Jan 22, 2025

Head to Head Survey: Aquestive Therapeutics (NASDAQ:AQST) & Vistagen Therapeutics (NASDAQ:VTGN) - Defense World

Jan 22, 2025

Jan 16, 2025

Jane Street Group LLC Purchases Shares of 19,659 Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Jan 16, 2025

Jan 15, 2025

Vistagen reports positive outcomes from Phase IIA cancer cachexia trial - Yahoo Finance

Jan 15, 2025

Jan 14, 2025

Vistagen reports promising PH284 nasal spray study By Investing.com - Investing.com Canada

Jan 14, 2025

Jan 14, 2025

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia - sharewise

Jan 14, 2025

Jan 14, 2025

Vistagen reports promising PH284 nasal spray study - Investing.com

Jan 14, 2025